Arabic Arabic English English French French German German
dark

BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure

BenevolentAI , a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Spago Nanomedicals Phase 1 Study with SpagoPix Shows Clear Contrast Enhancement and is Expanded into New Indications

Next Post

Abivax Receives EMA Scientific Advice Supportive of Moving ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Related Posts
Total
0
Share